Open Clinical Trials

Below you can find information about clinical trials currently open at our three sites:

  • Cork University Hospital (CUH)
  • Bon Secours Hospital Cork (BSH)
  • University Hospital Waterford (UHW)

If you have questions or queries, please contact the relevant research nurse assigned to each site.

NEW TRIALS OPENED

FORTIFI-HN01 (BCA101X301)

CUH

INSPIRE

BSH

Updated: June 30th 2026

Open Clinical Trials

If you are interested in taking part in a trial, we strongly encourage you to discuss it with your consulting medical team.

Information Last Updated: June 30th

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
TAORMINA This study compares the efficacy and toxicity of standard 1st line systemic therapy for breast cancer (BC) patients with or without the addition of stereotactic ablative body radiation therapy (SABR) to all the oligometastatic sites.   Participants with Oligometastatic Breast Cancer (OMBC) 

BSH 

 Click
here
Shamrock
study 		 Study to assess the effectiveness of a study drug called trastuzumab deruxtecan (T-DXd)  before definite surgery in patients with early stage locally advanced HER2 positive breast cancer. Participants with newly diagnosed early stage HER2-positive breast cancer with tumour size larger than 2cm 

CUH

 Click
here
Proteomics
study 		 Breast Cancer Proteomics and Molecular Heterogeneity  All newly diagnosed participants with blood cancer, recurrent and stage IV metastatic breast cancer patient  CUH (on hold) Click
here
TREAT ctDNA  This study compares elacestrant with standard endocrine therapy in patients who test ctDNA-positive but show no signs of metastasis or recurrence. Eligible patients are randomly assigned to continue their current treatment or switch to elacestrant. The study aims to evaluate which approach is more effective.  Participants with ER+/HER2- early-stage breast cancer with ctDNA relapse.  UHW  Click
here
MINA  Study to evaluate how bacteria in the Breast and Tumor Markers affect treatment response in patients with Triple-Negative Breast Cancer. Particpiants with cancer undergoing standard treatment for triple negative breast cancer  CUH Available on request
ASCENT-05  A study to compare Sacituzumab Govitecan and Pembrolizumab to Standard Treatment in Patients with Triple-Negative Breast Cancer who have residual invasive disease after surgery and neoadjuvant therapy.  High-risk early triple negative breast cancer (TNBC) without mutations in the BRCA1 or BRCA2 gene.  CUH Click here 
MK2870-012  A clinical trial to compare the effectiveness and safety of a new treatment combining two medicines (MK-2870 and pembrolizumab) with standard treatment chosen by a doctor.  Participants With Triple-Negative Breast Cancer  BSH Click here
DESTINY-Breast15  A clinical trial to evaluate drug called Trastuzumab Deruxtecan (T-DXd) in people with advanced breast cancer that is HER2-low or HER2-0 (a specific type of breast cancer).  Participants with unresectable and/or metastatic, advanced breast cancer that is HER2-low or HER2-0 (a specific type of breast cancer)  CUH Click here
         
MK2870-010  A study to to compare sacituzumab tirumotecan (study drug) as a single agent, and in combination with pembrolizumab, versus Treatment of Physician’s Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.  Participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.  BSH Click here
DEFINITIVE  Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer  Participants with early-stage HER2-positive Breast cancer 

UHW

CUH

 Click here

 

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
KRYSTAL-7  A clinical study testing the cancer drug Adagrasib alone and with Pembrolizumab in patients with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C mutation). The study will also compare the combination of Adagrasib and Pembrolizumab to Pembrolizumab alone to see which works better.  Participants with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation  UHW Click here
V940-009 This study is investigating whether intismeran autogene plus pembrolizumabcan help people with non-small cell lung cancer (NSCLC) stay cancer-free longer after surgery, compared to placebo plus pembrolizumab.   Participants with resectable Stages II-IIIB (N2) NSCLC who have not achieved a pCR CUH Click here

CA239-0004 (KRYSTAL-04) 

 

This study to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation 

Participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation 

CUH 

 

Click here 
         

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
         
MOUNTAINEER-03  Study comparing a drug called Tucatinib in Combination with Trastuzumab and mFOLFOX6 Versus mFOLFOX6 given with or without Either Cetuximab or Bevacizumab as first-line Treatment for Subjects with HER2+ Metastatic Colorectal
Cancer 		 Locally advanced unresectable HER2 Positive colorectal cancer  
UHW
BSH
CUH
Click
here
         

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
CA071-1000 (rechARge)  This study is to compare the efficacy and safety of BMS-986365 versus the investigator’s choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.  Participants with Metastatic Castration-resistant Prostate Cancer.  CUH Click here
MK2400-001  This study is to compare the study drug Ifinatamab Deruxtecan with standard treatments for Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)  Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) CUH Click here
De-Escalate  This study is to determine whether intermittent hormonal combintation treatment provides a favorable risk/benefit balance compared with continuous maximum androgen blockade (cMAB) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) who achieve a deep PSA response (≤ 0.2 ng/mL) after 6–12 months of treatment with ADT plus an approved androgen receptor pathway inhibitor (ARpI)  For patients being treated for prostate cancer that has spread and who have had a good response to a standard of care hormonal combination treatment  CUH Click here
PACE
NODES (UPMC, Bons)		 Study will look at the safety of curative radiotherapy to the prostate and lymph glands given in 5 visits, in men with high risk localised prostate cancer Patients with high risk localised prostate cancer, deemed suitable for SBRT radiotherapy and planned for 12 – 36 months androgen deprivation therapy BSH Click
here
MK 5684-01A  A clinical trial testing a drug called MK-5684—either by itself or in combination with other treatments in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC)  Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)  CUH Click here 
INSPIRE  INnovative SABR for Prostate cancer all IREland  Participants with prostate adenocarcinoma (prostate cancer) BSH Click here
MK6482-033 (LITESPARK033) Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy Participants with Locally Advanced or Metastatic RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy CUH Click here

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
Uveal Melanoma Development and characterisation of ex vivo culture models
of metastatic uveal melanoma		 Development and characterisation of ex vivo culture models
of metastatic uveal melanoma		 UHW Available on request
         
         
         

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
ENGOT-EN20/
GOG-3083/ XPORT-EC-042  		 Study to evaluate the efficacy and safety of study drug called Selinexor as a maintenance therapy in patients with endometrial carcinoma (EC)  Patients with endometrial carcinoma (EC), who have achieved a partial response (PR) or complet response (CR) after completing at least 12 weeks of platinum-based therapy 

CUH

 Click
here
TROFUSE-033 Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer  Participants with Mismatch Repair Proficient Endometrial Cancer CUH Click here
         
         
         

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO

FORTIFI-HN01 

(BCA101X301) 

 This study is to evaluate the safety and efficacy of the use of a drug called ficerafusp alfa (BCA101) in combination with the immunotherapy drug pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).  Participants with confirmed recurrent or metatastic HNSCC, with primary locations in the oral cavity, hypopharynx, larynx or oropharynx.  CUH Click here

Basket trials are clinical trials which cannot be categorised based on one specific disease category.

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
Microbiome study  To predict response to cancer therapies using microbiome biomarkers  Patient advocates with cancer with life expectancy more than 3 months, with any line of palliative ICI alone or in combination with Tyrosine Kinase Inhibitors (TKI) and/or cytotoxic chemotherapy  BSH Available
on request
Simplify SABR Comet Stereotactic Ablative Radiotherapy (SABR) is a modern technique that delivers high-dose radiation using precise 3D imaging (CT, MRI, PET) to target small tumors while sparing healthy tissue. Treatment can be given in multiple sessions (multi-fraction SABR) or a single session (single-fraction SABR). Participants with one controlled primary tumour and 1-5 oligometastatic or oligoprogressive lesions.
CUH
BSH 
Click here
         
         
         
         

TRIAL NAME AIM OF STUDY FOR PARTICIPANTS WITH  TRIAL SITES  More Info 
         
EMN39 (LINKER MM6)  This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible).  Participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible).  CUH Click here
HOVON 177  This study to assess revumenib in combination with azacitidine + venetoclax in adult participants with newly diagnosed NPM1-mutated or KMT2A- Adult participants with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy 

UHW 

CUH 
Click here
CLL18  A study to analyse different combinations of cancer drugs to treat chronic lymphocytic leukemia (CLL) in people who haven’t had treatment before. It compares fixed-duration treatments with a personalized approach that stops treatment early if the cancer becomes undetectable. The goal is to find the most effective and safest way to treat CLL while minimizing side effects and improving quality of life.  For participants with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) 

UHW 

CUH 
Click here
EVOLVE-1 (HOVON 173)  Ivosidenib and Azacitidine With or Without Venetoclax in Adult Participants With Newly Diagnosed IDH1-Mutated AML or MDS/AML considered Ineligible for Intensive Chemotherapy Participants With Newly Diagnosed IDH1-Mutated AML or MDS/AML considered Ineligible for Intensive Chemotherapy  CUH Click here
Mahogany (Beigene 311-308)  Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients with Relapsed/Refractory Follicular or Marginal Zone Lymphoma  Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma  UHW Click Here
Discontinuation Study Discontinuation of Lenalidomide maintenance for the patients diagnosed with multiple myeloma in sustainable Minimal Residual disease (MRD) negative remission without high–risk features  Patients diagnosed with multiple myeloma (MM) without high–risk feature and who have completed at least 2 years on maintenance therapy with lenalidomide  CUH Available
on request
CC-92480-MM-003 (CA057-001)/ SUCCESSOR  Study to evaluate the safety and efficacy of study drugs called mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd)  Participants with multiple myeloma that have not responded well to the treatment/that has come back after the treatment and who have tried between 1 to 3 treatments before, and have used lenalidomide before  CUH Click Here
Regeneron 2257  A Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk SmolderingMultiple Myeloma  Participants with high-risk monoclonal gammopathy of undetermined significance or non-high-risk smoldering multiple myeloma  CUH Click Here
EMN30 MajesTEC-4  Study to  evaluate the benefits of study drug called teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant. Participants with newly diagnosed multiple myeloma CUH  Click Here

Italfarmaco /GIV-IN PV 

 A study comparing two treatments (GIVinostat and hydroxyurea) for participants with high-risk polycythemia vera  Participants with with JAK2V617F-positive high-risk polycythemia vera  CUH Click Here

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
IMPROVE-TMZ  Investigating Mechanistic PRedictors Of Interpatient Variability and temozolomide (TMZ) induced haematological toxicity for glioma patients. (IMPROVE TMZ) Glioma patients who are being started on temozolomide treatment or who have been treated with temozolomide and developed a haematological toxicity
CUH 
UHW 
Available on request 
Spine SABR (UPMC, Bons)  Study to determine the maximum tolerated dose of stereotactic radiotherapy, to the spine, delivered in two fractions with a simultaneous integrated boost technique, for patients with oligometastatic or oligoprogressive spine disease.  Participants with oligometastatic disease (OMD) or oligoprogressive disease (OPD) solid tumour spine metastases  BSH Click here
NRG BN013 Phase III trial of single fraction stereotactic radiosurgery (SRS) versus fractionated SRS (FSRS) for intact brain metastases Participants with intact brain metastases
CUH 
BSH 
Click here

Biobanking

A biobank is a facility where biological samples such as blood, tissue, and DNA are stored for research purposes. They aid in advancing medical knowledge and developing new treatments.

TRIAL NAME AIM OF THE STUDY FOR PARTICIPANTS WITH TRIAL SITES MORE INFO
BCNI
Biobank 		 Blood Cancer Biobank Ireland (BCBI) sample collection and management  All newly diagnosed CLL (Chronic lymphocytic leukaemia), AML (Acute myeloid leukaemia) and MM (Multiple myeloma) patients who have not yet received any treatment 

CUH

UHW

 Click
here
GEM The Impact of Genetic Expression Profile on Depth of Response and Survival In Multiple Myeloma  All newly diagnosed Multiple Myeloma participants who are eligible for autologous stem cell transplant  UHW Available on request 
LYM-MAP  The use of cell free DNA in High Grade non-Hodgkin’s lymphoma in conjunction with FDG PET CT scan parameters  All newly diagnosed and relapsed High-Grade non Hodgkin Lymphoma patients over the age of 16 may be included 

CUH

 Available on request 
         

 

Key Terms

Adjuvant treatment: Adjuvant treatment refers to additional therapy administered following the primary treatment to reduce the risk of cancer recurrence.

Placebo: A placebo is an inert substance or treatment given to individuals in a clinical study to assess the true effects of a specific treatment. It serves as a control to differentiate between the effects of the active treatment and the psychological response of the participants.

Maintenance therapy: Maintenance therapy involves continued treatment after the initial therapy, often at lower doses, to sustain the response achieved and prevent disease progression or recurrence.

Relapse: Relapse is the return of signs and symptoms of a disease after a period of improvement or remission.

Proteomics: Refers to the study of proteins in the body.

Microbiome: The microbiome refers to all the tiny living organisms, like bacteria, viruses, and fungi, that live in and on our bodies. These microorganisms play a big role in keeping us healthy by helping with digestion, protecting against harmful germs, and even influencing our mood and immune system.

Menopause: Menopause is when your periods stop due to lower hormone levels. It usually affects women between the ages of 45 and 55, but it can happen earlier.

A Window-of-Opportunity Trial: A window-of-opportunity study is a type of clinical research done over a short period of time, usually between the time of diagnosis and the surgery.

Oligometastatic breast cancer (OMBC): Oligometastatic breast cancer (OMBC) is defined as the presence of 1-5 metastasis in up to 2 organs in the body. 

Neoadjuant Therapy: This refers to treatment given before surgery to shrink a tumor or improve the chances of a successful operation. 

Mismatch Repair Proficient Endometrial Cancer: Advanced or recurring Endometrial Cancer whose cancer has a “normal” mismatch-repair system.

If you have questions or queries, please contact the relevant research nurse assigned to each site.

Bons Secours Hospital

Lisa Stacklmstack@bonsecours.ie

Cork University Hospital

Debra O’Hare debrad.ohare@hse.ie

Waterford University Hospital

Flordeliza Calacsan flordeliza.calacsan@hse.ie

Contact Sites

Bons Secours Hospital

Lisa Stack lmstack@bonsecours.ie

021 4542807 ext: 2663

Oncology Clinical Trials Department, Bon Secours Hospital, College Rd, Cork

Cork University Hospital

Debra O’Hare debrad.ohare@hse.ie

021 4234816

Cancer Trials Unit-Glandore Dept, Cork University Hospital Wilton, Cork

Waterford University Hospital

Flordeliza Calacsan flordeliza.calacsan@hse.ie

Lauren Clarke lauren.clarke@hse.ie

Dunmore Road, Waterford City

Where can I find the trials available in Ireland?

Cancer Trials Ireland provides further information about ongoing trials in Ireland.

Learn more

Thinking of taking part in a clinical trial?

See if you are eligible for a trial, and consider the pros and cons of participating.

Learn more

EU Clinical Trial Map

A new Clinical Trial Map provides patients and healthcare professionals with easy access to real-time, detailed information about clinical trials across the EU.

Learn more